Drug Interaction:
Antineuoplastic agents include-
Amsacrine, carboplastin, cisplantin, crisantaspase, hydroyxurea, dacarbazine, procarbazine.
Refer- Hydroxyurea
Cumulative nephrotoxicity potentiated by aminoglycosides.
Coadministration with loop diuretics may have an additive ototoxic effect.
Combination therapy with phenytoin may reduce phenytoin plasma levels,requiring an increased dosage to maintain therapeutic plasma levels.
Lab/Test abnormalities- Alkaline phosphatases(24%); AST (15%); total bilurubin (5%).
Indication:
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Carboplatin Anticancer March 1989
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Carboplatin Cancer/Oncology Bristol-Meyers 14-04-2004
Squibb
Alkylating Agents Includes-
Mechlorethamine ,Chlorambucil, Melphalan, Ifosamide,Cyclophosphamide, Urasil Mustard,
Lomustine, Carmustine, Streptozocin, Thiotepa, Busulfan, Pipobroman, Cisplatin, Carboplatin
Adverse Reaction:
Bone marrow supression,thrombocytopenia.
Peripheral neuropathies, with parathesis occuring most frequently.
Hypersensitivity including rash, urticaria, erythema, pruritus.
Pain, asthenia, alopecia.
Contra-Indications:
History of severe allergic reactions to cisplatin or other platinum compds or mannitol,
severe bone marrow depression, bleeding.
Special precautions:
Aluminium can react with cisplatin, causing precipitate formation and loss of potency.
Do not use needles or IV admn containing aluminium parts that may come in contact with cisplatin for prepn or admin of the drug.
Dosages/ Overdosage Etc:
Approved by (DCI) Drug Controller GENERAL - India For Marketing (Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Carboplatin Anticancer March 1989
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Carboplatin Cancer/Oncology Bristol-Meyers 14-04-2004
Squibb
Indications:
Ovarian carcinoma
Dosage:
Aluminium reacts with carboplatin . Needles or IV set containing Aluminium should not used. 360mg/m2 IV on day 1 every 4 weeks.
Patient Information:
Antineuoplastic agents include- Amsacrine, carboplastin, cisplantin, crisantaspase, hydroyxurea, dacarbazine, procarbazine.
Carboplatin- Systemic
1.Allergies-
Tell your doctor if you are have ever had any unusual or allergic reaction to
carboplatin, cisplatin or any other platinum-containing substance
2.Pregnancy-
There is a chance that this medicine may cause birth defects if either the male
or the female is taking it at the time of conception or if it is taken during pregnancy.
Carboplatin causes toxic or harmful effects and birth defects in rats. In addition
many cancer medicines may cause sterility which could be permanent.
Although sterility has not been reported with this medicine, the possibility should
be kept in mind. Before receiving carboplatin make sure your doctor knows if you
are pregnant or if you may become pregnant
3. Breast-feeding-
Because carboplatin may cause serious side effects, breast feeding is generally
not recommended while you are receiving it
4.Children-
Studies of thie medicine have been done only in adult patients and there is no specific
information comparing carboplatin in children with use in other age groups.
5.Older adults-
Some side effects of carboplatin (especially blood pressure or numbness or tingling
in fingers or toes) may be more likely to occur in the elderly
6. Other medicines-
Although certain medicines should not be used together at all, in other cases two
different medicines may be used together even if an interaction might occur.
In such cases your doctor may want to change the dose, or other precautions
may be necessary.
When you receiving carboplatin it is especially important that your doctor know
if you have have been treated with radiation or cancer medicines or if you are
taking any of the following-
Amphotericin B by injection or
Antithyroid agents ( medicines for overactive thyroid) or
Azathioprine or
Cochicine or
Flucytosine or
Gangiclovir or
Interferon or
Plicamycin or
Zidovudine - carboplatin may increase the effects of these medicines or
radiation on the blood
7. Other medical problems-
The presence of other medical problems may affect the use of carboplatin
Make sure you tell your doctor if you have any other medical problems
especially-
Chickenpox (recent exposure) or
Herpes Zoster ( shingles) -risk of severe disease affecting other parts
of the body
Hearing problems - may be worsened by carpboplatin
Infection- carboplatin decreases the bodys ability to fight infection
Kidney disease- effects may be increased because of slower removal
from the body
Pharmacology/ Pharmacokinetics:
Pharmacology:
Carboplatin is a platinum compound that is used as a cancer chemotherapeutic agent. Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA protein cross links.
Pharmacokinetics:
The initial plasma half-life is 1.1 to 2 hours, and the post distribution half-life is 2.6 to 5.9 hours. The major route of eliminatin is renal excretion.
Interaction with Food:
Not available
Pregnancy and lactation:
Antineuoplastic agents include- Amsacrine, carboplastin, cisplantin, crisantaspase, hydroyxurea, dacarbazine, procarbazine.
Refer- Hydroxyurea
Manufacturer Details